Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309646522> ?p ?o ?g. }
- W4309646522 abstract "Abstract Background This retrospective cohort study assessed benefits and risks of bedaquiline treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating safety, effectiveness, drug utilization and emergence of resistance to bedaquiline. Methods Data were extracted from a register of South African drug-resistant-tuberculosis (DR-TB) patients (Electronic DR-TB Register [EDRWeb]) for newly diagnosed patients with MDR-TB (including pre-extensively drug-resistant [XDR]-TB and XDR-TB and excluding rifampicin-mono-resistant [RR]-TB, as these patients are by definition not multidrug-resistant), receiving either a bedaquiline-containing or non-bedaquiline-containing regimen, at 14 sites in South Africa. Total duration of treatment and follow-up was up to 30 months, including 6 months’ bedaquiline treatment. WHO treatment outcomes within 6 months after end-of-treatment were assessed in both patient groups. Longer term mortality (up to 30 months from treatment start) was evaluated through matching to the South African National Vital Statistics Register. Multivariable Cox proportional hazards analyses were used to predict association between receiving a bedaquiline-containing regimen and treatment outcome. Results Data were extracted from EDRWeb for 5981 MDR-TB patients (N = 3747 bedaquiline-treated; N = 2234 non-bedaquiline-treated) who initiated treatment between 2015 and 2017, of whom 40.7% versus 80.6% had MDR-TB. More bedaquiline-treated than non-bedaquiline-treated patients had pre-XDR-TB (27.7% versus 9.5%) and XDR-TB (31.5% versus 9.9%) per pre-2021 WHO definitions. Most patients with treatment duration data (94.3%) received bedaquiline for 6 months. Treatment success (per pre-2021 WHO definitions) was achieved in 66.9% of bedaquiline-treated and 49.4% of non-bedaquiline-treated patients. Death was reported in fewer bedaquiline-treated (15.4%) than non-bedaquiline-treated (25.6%) patients. Bedaquiline-treated patients had increased likelihood of treatment success and decreased risk of mortality versus non-bedaquiline-treated patients. In patients with evaluable drug susceptibility testing data, 3.5% of bedaquiline-susceptible isolates at baseline acquired phenotypic resistance. Few patients reported bedaquiline-related treatment-emergent adverse events (TEAEs) (1.8%), TEAE-related bedaquiline discontinuations (1.4%) and QTcF values > 500 ms (2.5%) during treatment. Conclusion Data from this large cohort of South African patients with MDR-TB showed treatment with bedaquiline-containing regimens was associated with survival and effectiveness benefit compared with non-bedaquiline-containing regimens. No new safety signals were detected. These data are consistent with the positive risk–benefit profile of bedaquiline and warrant continued implementation in combination therapy for MDR-TB treatment." @default.
- W4309646522 created "2022-11-29" @default.
- W4309646522 creator A5007003687 @default.
- W4309646522 creator A5010705038 @default.
- W4309646522 creator A5019702306 @default.
- W4309646522 creator A5022928212 @default.
- W4309646522 creator A5023581417 @default.
- W4309646522 creator A5026258761 @default.
- W4309646522 creator A5032225287 @default.
- W4309646522 creator A5033085096 @default.
- W4309646522 creator A5035173342 @default.
- W4309646522 creator A5048663337 @default.
- W4309646522 creator A5060068641 @default.
- W4309646522 creator A5060645267 @default.
- W4309646522 creator A5061542692 @default.
- W4309646522 creator A5090444369 @default.
- W4309646522 date "2022-11-21" @default.
- W4309646522 modified "2023-10-18" @default.
- W4309646522 title "Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis" @default.
- W4309646522 cites W1768860766 @default.
- W4309646522 cites W1964919338 @default.
- W4309646522 cites W2047720317 @default.
- W4309646522 cites W2055092907 @default.
- W4309646522 cites W2064708864 @default.
- W4309646522 cites W2107340859 @default.
- W4309646522 cites W2127258416 @default.
- W4309646522 cites W2158658436 @default.
- W4309646522 cites W2262666571 @default.
- W4309646522 cites W2318000940 @default.
- W4309646522 cites W2563852803 @default.
- W4309646522 cites W2586809595 @default.
- W4309646522 cites W2616064604 @default.
- W4309646522 cites W2799631683 @default.
- W4309646522 cites W2859364562 @default.
- W4309646522 cites W2891690058 @default.
- W4309646522 cites W2898276975 @default.
- W4309646522 cites W2923022813 @default.
- W4309646522 cites W2951105164 @default.
- W4309646522 cites W3009599329 @default.
- W4309646522 cites W3038356802 @default.
- W4309646522 cites W3097743599 @default.
- W4309646522 cites W3154622831 @default.
- W4309646522 cites W3191327872 @default.
- W4309646522 cites W3212793290 @default.
- W4309646522 doi "https://doi.org/10.1186/s12879-022-07861-x" @default.
- W4309646522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36414938" @default.
- W4309646522 hasPublicationYear "2022" @default.
- W4309646522 type Work @default.
- W4309646522 citedByCount "7" @default.
- W4309646522 countsByYear W43096465222023 @default.
- W4309646522 crossrefType "journal-article" @default.
- W4309646522 hasAuthorship W4309646522A5007003687 @default.
- W4309646522 hasAuthorship W4309646522A5010705038 @default.
- W4309646522 hasAuthorship W4309646522A5019702306 @default.
- W4309646522 hasAuthorship W4309646522A5022928212 @default.
- W4309646522 hasAuthorship W4309646522A5023581417 @default.
- W4309646522 hasAuthorship W4309646522A5026258761 @default.
- W4309646522 hasAuthorship W4309646522A5032225287 @default.
- W4309646522 hasAuthorship W4309646522A5033085096 @default.
- W4309646522 hasAuthorship W4309646522A5035173342 @default.
- W4309646522 hasAuthorship W4309646522A5048663337 @default.
- W4309646522 hasAuthorship W4309646522A5060068641 @default.
- W4309646522 hasAuthorship W4309646522A5060645267 @default.
- W4309646522 hasAuthorship W4309646522A5061542692 @default.
- W4309646522 hasAuthorship W4309646522A5090444369 @default.
- W4309646522 hasBestOaLocation W43096465221 @default.
- W4309646522 hasConcept C114851261 @default.
- W4309646522 hasConcept C126322002 @default.
- W4309646522 hasConcept C133936738 @default.
- W4309646522 hasConcept C141071460 @default.
- W4309646522 hasConcept C142724271 @default.
- W4309646522 hasConcept C167135981 @default.
- W4309646522 hasConcept C2776301714 @default.
- W4309646522 hasConcept C2777107064 @default.
- W4309646522 hasConcept C2777768864 @default.
- W4309646522 hasConcept C2777975735 @default.
- W4309646522 hasConcept C2780544761 @default.
- W4309646522 hasConcept C2781069245 @default.
- W4309646522 hasConcept C2781413609 @default.
- W4309646522 hasConcept C71924100 @default.
- W4309646522 hasConcept C72563966 @default.
- W4309646522 hasConcept C86803240 @default.
- W4309646522 hasConcept C89423630 @default.
- W4309646522 hasConceptScore W4309646522C114851261 @default.
- W4309646522 hasConceptScore W4309646522C126322002 @default.
- W4309646522 hasConceptScore W4309646522C133936738 @default.
- W4309646522 hasConceptScore W4309646522C141071460 @default.
- W4309646522 hasConceptScore W4309646522C142724271 @default.
- W4309646522 hasConceptScore W4309646522C167135981 @default.
- W4309646522 hasConceptScore W4309646522C2776301714 @default.
- W4309646522 hasConceptScore W4309646522C2777107064 @default.
- W4309646522 hasConceptScore W4309646522C2777768864 @default.
- W4309646522 hasConceptScore W4309646522C2777975735 @default.
- W4309646522 hasConceptScore W4309646522C2780544761 @default.
- W4309646522 hasConceptScore W4309646522C2781069245 @default.
- W4309646522 hasConceptScore W4309646522C2781413609 @default.
- W4309646522 hasConceptScore W4309646522C71924100 @default.
- W4309646522 hasConceptScore W4309646522C72563966 @default.
- W4309646522 hasConceptScore W4309646522C86803240 @default.
- W4309646522 hasConceptScore W4309646522C89423630 @default.